Skip to Content
Morningstar

Novartis AG Registered Shares NOVN

Morningstar Rating
Unlock
Stock XSWX Rating as of
CHF 89.05 +0.18 (0.20%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Price vs Fair Value

View History
NOVN is trading at a 7% discount.
Price
CHF 89.05
Fair Value
CHF 49.00
Uncertainty
Medium
1-Star Price
CHF 588.40
5-Star Price
CHF 73.30
Economic Moat
Dhtq
Capital Allocation
Khpvqzrx

Bulls Say, Bears Say

Bulls

Novartis' solid late-stage pipeline should propel long-term growth. The company should launch several new drugs during the next several years in critical therapeutic areas such as rare diseases and oncology.

Bears

The patent loss on multiple sclerosis drug Gilenya creates a significant drag on sales in 2023-24 as generic competition increases.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NOVN is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
CHF 88.87
Day Range
CHF 88.63–89.51
52-Week Range
CHF 79.21–94.52
Bid/Ask
CHF 0.00 / CHF 0.00
Market Cap
CHF 181.70 Bil
Volume/Avg
2.9 Mil / 3.3 Mil

Key Statistics

Price/Earnings (Normalized)
14.57
Price/Sales
4.18
Dividend Yield (Trailing)
3.71%
Dividend Yield (Forward)
3.71%
Total Yield
7.09%

Company Profile

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
76,057
Website
https://www.novartis.com

Competitors

Valuation

View More
Metric
NOVN
GSK
JNJ
Price/Earnings (Normalized)
 14.5710.7513.82
Price/Book Value
 5.084.845.06
Price/Sales
 4.182.264.06
Price/Cash Flow
 13.8710.7618.25
Price/Earnings
NOVN
GSK
JNJ

Financial Strength

Metric
NOVN
GSK
JNJ
Quick Ratio
 0.880.570.84
Current Ratio
 1.160.871.17
Interest Coverage
 10.948.9423.57
Quick Ratio
NOVN
GSK
JNJ

Profitability

Metric
NOVN
GSK
JNJ
Return on Assets (Normalized)
 13.39%12.12%14.14%
Return on Equity (Normalized)
 31.09%55.16%35.47%
Return on Invested Capital (Normalized)
 19.67%24.00%22.55%
Return on Assets
NOVN
GSK
JNJ
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - General Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoKnkypsfydNbn$742.4 Bil
JNJ
Johnson & JohnsonXshsvprvFxhz$348.4 Bil
MRK
Merck & Co IncLnjtyhqzBqpr$327.3 Bil
ABBV
AbbVie IncJxgjdgmhCxkl$288.0 Bil
AZN
AstraZeneca PLC ADRBbjwqmsxnGmvys$234.8 Bil
NVS
Novartis AG ADRWvncmtnfkVfk$199.4 Bil
RHHBY
Roche Holding AG ADRGpxwpmpvtFtl$195.4 Bil
AMGN
Amgen IncYpxctxfhlZcdz$146.9 Bil
PFE
Pfizer IncQqsbphpmbNfkw$145.1 Bil
SNY
Sanofi SA ADRQpbtlntBpzlv$124.5 Bil

Sponsor Center